av/natco-pharma--big.svg

NSE:NATCOPHARM

NATCO Pharma

  • Stock

INR

Last Close

1,357.60

25/11 09:40

Market Cap

212.46B

Beta: 0.42

Volume Today

445.59K

Avg: 330.36K

PE Ratio

13.65

PFCF: -

Dividend Yield

1.11%

Payout:0%

Company Overview

Metric
Company NameNATCO Pharma Limited
SymbolNATCOPHARM
MSH IDIN:CO:NATCOPHARMA
MarketSTOCKS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CountryIN
Stage
Employee Count3.95K
Websitenatcopharma.co.in
LinkedInnatcopharma
Founders

Market Metrics

Metric
Market Cap2.51B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Financial Performance

Metric
Revenue472.10M
Revenue (LTM)
Revenue (NTM)
Gross Profit303.46M
EBITDA206.77M
Operating Income184.72M
Net Income163.90M
EPS0.91
Diluted EPS0.91
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Growth Metrics

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Profitability Ratios

Metric
Gross Profit Margin0.78
Operating Profit Margin0.45
EBITDA Margin0.44
Net Profit Margin0.39
Return on Equity0.34
Return on Assets0.24
Return on Capital Employed0.32

Valuation Multiples

Metric
P/E Ratio13.65
P/B Ratio2.91
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio6.76
EV Multiple14.84

Operational Metrics

Metric
Days Sales Outstanding115.65
Days Payables Outstanding170.09
Days Inventory Outstanding279.56
Operating Cycle388.90
Cash Conversion Cycle294.91
Asset Turnover0.61

Cash Flow Metrics

Metric
Operating Cash Flow147.85M
Free Cash Flow105.50M
Cash Flow to Debt0.94
Operating Cash Flow/Sales0.09
Free Cash Flow Yield

Balance Sheet Metrics

Metric
Cash & Equivalents112.50M
Accounts Receivable-40.29M
Inventory82.70M
Goodwill6.61M
Debt to Capitalization0.06
Debt to Assets0.04
Current Ratio3.81
Quick Ratio3.42

Efficiency Metrics

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue